LENZ Therapeutics' Vizz Approval Sets Stage for Commercial Potential

LENZ Therapeutics received FDA approval for Vizz eye drops, positioning the company for significant commercial potential in the presbyopia treatment market. The approval replaces regulatory uncertainty with commercial execution risks, changing the investment narrative from regulatory to commercial success. Investors should be mindful of execution hurdles, patient adoption rates, and limited revenue base. Shares may still be trading above fair value, and there could be more downside.